8.4 Gestational Diabetes Mellitus (GDM): Screening, Diagnostic Criteria & Management
Key Takeaways
Gestational diabetes mellitus (GDM) arises when maternal pancreatic beta-cell insulin secretion fails to compensate for pregnancy-induced insulin resistance driven by placental hormones (hPL, progesterone, cortisol).
NICE NG3 offers a 75 g OGTT at 24–28 weeks to women with risk factors; women with previous GDM have early glucose monitoring or an OGTT as soon as possible after booking.
The NICE NG3 diagnostic criteria for GDM are a fasting plasma glucose ≥5.6 mmol/L or a 2-hour plasma glucose ≥7.8 mmol/L.
Management follows a stepped ladder: diet and exercise first-line, metformin if targets are not met within 1-2 weeks, and immediate insulin if fasting glucose is ≥7.0 mmol/L at diagnosis or if macrosomia/polyhydramnios develops.
Intrapartum glycaemic control targets capillary blood glucose between 4.0 and 7.0 mmol/L using a Variable Rate Intravenous Insulin Infusion (VRIII) if required; all diabetic medications cease immediately after placental expulsion.
Gestational Diabetes Mellitus (GDM): Screening, Diagnostic Criteria & Management
Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance of variable severity with onset or first recognition during pregnancy. It affects approximately 5% to 10% of pregnancies in the United Kingdom, with increasing prevalence driven by advanced maternal age and obesity. Evidence-based care under NICE guideline NG3 (Diabetes in pregnancy: management from preconception to the postnatal period) prevents maternal and fetal morbidity, including pre-eclampsia, fetal macrosomia, shoulder dystocia, birth trauma, and neonatal metabolic collapse.
Pathophysiology of Gestational Insulin Resistance
Pregnancy is a state of physiological, progressive insulin resistance designed by evolution to ensure continuous nutrient delivery to the rapidly developing fetus:
- Placental Counter-Regulatory Hormones: Beginning in early pregnancy and accelerating sharply from mid-gestation (20–24 weeks onwards), the syncytiotrophoblast secretes large quantities of anti-insulin hormones: human placental lactogen (hPL), human placental growth hormone (hPGH), progesterone, cortisol, prolactin, and inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α).
- Post-Receptor Insulin Desensitization: These hormones disrupt post-receptor insulin signalling pathways in maternal skeletal muscle, adipose tissue, and liver, reducing maternal glucose uptake by up to 50%.
- Facilitated Glucose Transport: Maternal glucose crosses the placental syncytiotrophoblast along a concentration gradient via carrier-mediated facilitated diffusion using GLUT1 glucose transporters. In contrast, maternal insulin does not cross the placenta.
- Pancreatic Beta-Cell Compensation vs. Failure: In a healthy pregnancy, maternal pancreatic beta-cells undergo hypertrophy and hyperplasia, increasing insulin secretion by two- to three-fold to maintain normal glycaemic levels. When maternal beta-cells possess inadequate functional reserve to overcome this physiological insulin resistance, maternal hyperglycaemia and GDM develop.
- The Pedersen Hypothesis: Maternal hyperglycaemia results in excess glucose transfer to the fetus. In response to fetal hyperglycaemia, the fetal pancreas secretes endogenous insulin from 12–14 weeks' gestation. Fetal hyperinsulinaemia acts as a powerful anabolic growth hormone, driving accelerated protein synthesis, somatic overgrowth (macrosomia), organomegaly (cardiomegaly, hepatosplenomegaly), selective adipose deposition across the shoulders and abdomen, and elevated oxygen consumption leading to fetal hypoxia, erythropoietin surge, polycythaemia, and neonatal jaundice.
Selective Risk-Factor Based Screening (NICE NG3)
The UK National Screening Committee (UK NSC) and NICE guideline NG3 do not recommend universal screening for GDM. Instead, the NHS operates a selective, risk-factor based screening strategy. Midwives must systematically assess all women at the initial booking visit for the presence of 5 core risk factors:
- Body Mass Index (BMI): Booking BMI ≥30 kg/m².
- Previous Macrosomic Infant: History of giving birth to a previous infant weighing ≥4.5 kg (or >90th centile).
- Previous Gestational Diabetes: Documented history of GDM in a previous pregnancy.
- Family History of Diabetes: First-degree relative (parent, sibling, or child) with Type 1 or Type 2 diabetes mellitus.
- High-Prevalence Ethnicity: Minority ethnic origin with a high prevalence of diabetes: South Asian (Indian, Pakistani, Bangladeshi), Black Caribbean, or Middle Eastern.
Additional Opportunistic Screening Prompt: Glycosuria
Routine antenatal dipstick urinalysis at every appointment acts as an ongoing opportunistic screen. If urinalysis reveals glycosuria of 2+ or more on 1 occasion, or glycosuria of 1+ on 2 or more occasions, further investigation with an OGTT is indicated even in the absence of initial booking risk factors.
The 2-Hour 75 g Oral Glucose Tolerance Test (OGTT)
1. Timing of Testing
- Standard Cohort: Women with any of the 5 booking risk factors (or emergent glycosuria) are offered a 2-hour 75 g Oral Glucose Tolerance Test (OGTT) at 24 to 28 weeks' gestation.
- Women with Previous GDM: Because of a high recurrence risk, women with a history of GDM are offered early self-monitoring of blood glucose or a 75 g OGTT as soon as possible after booking (whether in the first or second trimester), according to NICE NG3. If this early test is normal, a further 75 g OGTT is offered at 24 to 28 weeks.
2. Testing Protocol & NICE NG3 Diagnostic Criteria
The woman fasts overnight (water permitted). A baseline fasting venous plasma sample is drawn, followed by ingestion of 75 g anhydrous glucose dissolved in water over 5 minutes. A second venous sample is collected exactly 2 hours post-load.
| Diagnostic Threshold (NICE NG3) | Venous Plasma Glucose Value |
|---|---|
| Fasting Plasma Glucose | ≥ 5.6 mmol/L |
| 2-Hour Plasma Glucose | ≥ 7.8 mmol/L |
Important
Under NICE guideline NG3, a diagnosis of gestational diabetes is confirmed if EITHER the fasting plasma glucose is ≥5.6 mmol/L OR the 2-hour plasma glucose is ≥7.8 mmol/L. Only one abnormal value is required to establish the diagnosis.
Home Blood Glucose Monitoring (HBGM) & Targets
Following diagnosis, the midwife introduces the woman to a dedicated multi-disciplinary joint diabetes-antenatal service. The woman is provided with a calibrated blood glucose meter and taught self-monitoring technique (fasting and 1-hour postprandial testing):
- Fasting Target: < 5.3 mmol/L (and ≥3.5 mmol/L)
- 1-Hour Postprandial Target: < 7.8 mmol/L
- (Alternative 2-hour postprandial target: <6.4 mmol/L)
Women treated with insulin are instructed to maintain blood glucose >4.0 mmol/L to avoid maternal hypoglycaemia ("four is the floor").
Stepped Pharmacological Management Ladder
NICE NG3 establishes a clear, tiered decision tree for initiating treatment based on the diagnostic fasting plasma glucose level and ultrasound findings:
Diagnostic Fasting Plasma Glucose Level:
├─ Fasting <7.0 mmol/L & No Fetal Complications:
│ └─ Trial of Lifestyle / Dietary Modification for 1 to 2 Weeks
│ ├─ Targets Achieved ──────> Continue Diet and Exercise
│ └─ Targets NOT Achieved ──> Add Oral Metformin
│ └─ Targets Still Unmet ──> Add Insulin
│
├─ Fasting ≥7.0 mmol/L at Diagnosis:
│ └─ Offer IMMEDIATE Insulin (with or without Metformin) + Diet/Exercise
│
└─ Fasting 6.0–6.9 mmol/L WITH Fetal Complications (Macrosomia or Polyhydramnios):
└─ Offer IMMEDIATE Insulin (with or without Metformin) + Diet/Exercise
1. Dietary & Lifestyle Modification
Referral to a registered specialist dietitian. The dietary prescription emphasizes low glycaemic index (GI) complex carbohydrates, portion control, distributed carbohydrate intake across three meals and two snacks, elimination of refined simple sugars, high dietary fibre, and at least 30 minutes of moderate walking exercise daily after meals.
2. Oral Metformin
- Mechanism: A biguanide that suppresses hepatic gluconeogenesis and enhances peripheral insulin sensitivity without stimulating endogenous pancreatic insulin secretion, carrying virtually no risk of maternal hypoglycaemia.
- Administration: Commenced at 500 mg once daily with food, titrated gradually over 1–2 weeks to 1,000 mg twice daily (2 g/day) to minimize gastrointestinal adverse effects (nausea, abdominal cramping, diarrhoea).
3. Insulin Therapy
- Indications: Initiated immediately if fasting glucose is ≥7.0 mmol/L at diagnosis; if fasting glucose is 6.0–6.9 mmol/L with ultrasound evidence of fetal macrosomia (abdominal circumference >95th centile) or polyhydramnios; or when lifestyle and metformin fail to achieve target blood glucose levels within 1–2 weeks.
- Regimens: Multiple daily injection regimens utilizing intermediate-acting basal insulin (NPH / Isophane or long-acting analogue Detemir) and rapid-acting mealtime analogues (Aspart or Lispro).
Fetal Surveillance & Timing of Birth
1. Fetal Ultrasound Monitoring
- Women with GDM are offered serial ultrasound growth scans every 4 weeks: at 28, 32, and 36 weeks' gestation.
- Biometric assessment focuses on fetal abdominal circumference (AC), estimated fetal weight (EFW), and amniotic fluid volume (deepest vertical pool or amniotic fluid index [AFI]) to detect asymmetrical macrosomia (disproportionate abdominal fat deposition) and polyhydramnios secondary to fetal polyuria.
2. Timing and Mode of Birth
- GDM (NICE NG3): Advise women with GDM to give birth no later than 40+6 weeks, and offer elective birth (induction of labour or caesarean section) to those who have not given birth by then.
- Earlier Birth: Consider elective birth before 40+6 weeks if there are maternal or fetal complications (for example, poor glycaemic control, hypertension, suspected macrosomia or FGR). Many units also set earlier timing for insulin-treated GDM under local protocols.
- Pre-existing Type 1 or Type 2 Diabetes: By contrast, NICE advises elective birth between 37+0 and 38+6 weeks.
- In women with suspected fetal macrosomia (EFW >4.5 kg), the risks and benefits of elective caesarean section versus trial of vaginal birth must be thoroughly discussed to reduce the hazard of permanent brachial plexus injury from shoulder dystocia.
Intrapartum Care & Glycaemic Control
During active labour, maternal glucose consumption rises while stress hormone surges can destabilize glycaemia. Maintaining strict euglycaemia is essential because maternal hyperglycaemia stimulates immediate fetal insulin secretion, which causes profound rebound neonatal hypoglycaemia within hours of birth once the maternal glucose supply is severed at umbilical cord clamping.
- Capillary Blood Glucose Target in Labour: 4.0 to 7.0 mmol/L.
- Monitoring Frequency: Capillary blood glucose is checked hourly in women with pre-existing diabetes or women with GDM on insulin/oral medication.
- Variable Rate Intravenous Insulin Infusion (VRIII): If maternal blood glucose rises above 7.0 mmol/L during established labour, initiate a VRIII (sliding scale insulin) alongside a companion infusion of 5% dextrose with 0.45% sodium chloride and potassium chloride administered via volumetric infusion pumps.
Postnatal Care & Long-Term Metabolic Implications
1. Immediate Cessation of Diabetic Pharmacotherapy
Delivery of the placenta removes the source of anti-insulin hormones (hPL, progesterone, cortisol), resulting in an instantaneous collapse of gestational insulin resistance.
Note
In women with GDM, ALL insulin and oral hypoglycaemic medications (metformin) must be discontinued immediately upon expulsion of the placenta. NICE NG3 advises testing blood glucose before transfer to community care to exclude persisting hyperglycaemia.
2. Prevention of Neonatal Hypoglycaemia
- Neonates of diabetic mothers are at extreme risk of hyperinsulinaemic hypoglycaemia.
- Institute uninterrupted skin-to-skin contact immediately after birth.
- Ensure the infant feeds (breast milk or infant formula) within 30 minutes of birth, and feeds regularly every 2 to 3 hours.
- Perform routine pre-feed capillary blood glucose monitoring from 2 to 4 hours of life. Blood glucose must be maintained ≥2.0 mmol/L.
3. Maternal Postnatal Screening & Future Health
- Women diagnosed with GDM have a markedly increased lifetime risk of developing Type 2 diabetes.
- Postnatal Glucose Testing: Offer a fasting plasma glucose test at 6 to 13 weeks postpartum (or an HbA1c test after 13 weeks postpartum).
- Advise annual HbA1c screening thereafter and promote long-term weight management, healthy nutrition, and regular exercise.
A 32-year-old woman with a booking BMI of 33 kg/m² attends for an oral glucose tolerance test (OGTT) using a 75 g glucose load. According to NICE guideline NG3, at what gestational age should this routine screening test be performed, and which set of plasma glucose values is diagnostic of gestational diabetes mellitus (GDM)?
Performed at 16–18 weeks; fasting plasma glucose ≥7.0 mmol/L or 2-hour plasma glucose ≥11.1 mmol/L
Performed at 24–28 weeks; fasting plasma glucose ≥5.6 mmol/L or 2-hour plasma glucose ≥7.8 mmol/L
Performed at 28–32 weeks; fasting plasma glucose ≥6.1 mmol/L or 2-hour plasma glucose ≥8.5 mmol/L
Performed at 20–22 weeks; fasting plasma glucose ≥5.1 mmol/L or 2-hour plasma glucose ≥8.0 mmol/L
A 29-year-old woman is diagnosed with gestational diabetes at 26 weeks' gestation with a fasting plasma glucose of 7.4 mmol/L and a 2-hour glucose of 9.2 mmol/L. She has no other medical co-morbidities. According to NICE guideline NG3, what is the appropriate initial pharmacological recommendation?
Prescribe oral glibenclamide 5 mg daily and reassess fasting levels in 4 weeks
Advise dietary and lifestyle modifications alone for 4 weeks before considering medication
Commence oral metformin 500 mg daily and withhold insulin unless the 2-hour postprandial glucose exceeds 11.0 mmol/L
Offer immediate treatment with insulin (with or without metformin) alongside dietary and exercise advice
A woman with gestational diabetes requiring insulin therapy is admitted in established active labour at 39 weeks' gestation. What is the target capillary blood glucose range during labour, and what instruction regarding diabetic medication must be provided immediately following delivery of the placenta?
Maintain capillary blood glucose between 4.0 and 7.0 mmol/L; discontinue all insulin immediately following expulsion of the placenta
Maintain capillary blood glucose between 7.0 and 10.0 mmol/L; reduce the insulin dose by 50% for 48 hours postpartum
Maintain capillary blood glucose between 3.0 and 5.0 mmol/L; continue subcutaneous insulin until the 6-week postnatal check
Maintain capillary blood glucose between 5.5 and 8.5 mmol/L; convert insulin to oral metformin immediately following birth
Sections you finish are checked off in the contents.